# Tevogen Inc. (TVGN) fundamentals

Data as of 2026-11-13. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $5.72, market value $388 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Tevogen Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.

## Profitability
- **Return on equity: 319.1%**. A 319.1% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.

## Growth
- **EPS growth (1 yr): -130.9%**. Earnings per share fell 130.9%.

## Financial health
- **Current ratio: 0.22** (quick 0.22). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Tevogen Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -76.2%** (YTD -65.4%, 3-mo -14.0%). The shares are down 76.2% over twelve months including dividends.
- **From 52-week high: -77.0%** (57.3% above the low). Trading 77% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 40**. An RSI of 40 is neutral.
- **Beta (1 yr): 1.55** (volatility 112%). Beta of 1.55 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TVGN · Page: https://foliofundamentals.com/stocks/tvgn

Not investment advice.